



#32/B  
MB  
11/25/97

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Kohn, et al.  
Serial No. : 08/225,478  
Filed : April 8, 1994  
For : Gene Therapy by Administration of Genetically Engineered CD34+ Cells Obtained from Cord Blood  
Group : 1819  
Examiner : Stanton

Assistant Commissioner of Patents  
Washington, D.C. 20231

May 22, 1997

Continued

AMENDMENT

SIR:

In response to the Office Action dated May 28, 1997, kindly amend the above-identified application as follows:

IN THE CLAIMS:

1. (Twice amended) A method of [providing] expressing a therapeutic [effect] agent in a human [patient], comprising:

1  
administering autologous CD34+ cells obtained from cord blood to said [patient] human, said autologous CD34+ cells having been genetically engineered to include at least one nucleic acid sequence encoding a therapeutic agent[, said autologous CD34+ cells being administered in an amount effective to provide said patient with an effective amount of said therapeutic agent by expression of said nucleic acid sequence in said patient].